High-Specificity CRISPR-Mediated Genome Engineering in Anti-BCMA Allogeneic CAR T Cells Suppresses Allograft Rejection in Preclinical Models.
Degagné É, Donohoue PD, Roy S, Scherer J, Fowler TW, Davis RT, Reyes GA, Kwong G, Stanaway M, Larroca Vicena V, Mutha D, Guo R, Edwards L, Schilling B, Shaw M, Smith SC, Kohrs B, Kufeldt HJ, Churchward G, Ruan F, Nyer DB, McSweeney K, Irby MJ, Fuller CK, Banh L, Toh MS, Thompson M, Owen ALG, An Z, Gradia S, Skoble J, Bryan M, Garner E, Kanner SB.
Degagné É, et al. Among authors: kanner sb.
Cancer Immunol Res. 2024 Apr 2;12(4):462-477. doi: 10.1158/2326-6066.CIR-23-0679.
Cancer Immunol Res. 2024.
PMID: 38345397
Free PMC article.